Downregulation of Mus81 as a novel prognostic biomarker for patients with colorectal carcinoma

Cancer Science

Volumn 102, Issue 2, 2011, Pages 472-477

  Wu, Fan ^a,b   Shirahata, Atsushi ^b   Sakuraba, Kazuma ^b   Kitamura, Yohei ^b   Goto, Tetsuhiro ^b   Saito, Mitsuo ^b   Ishibashi, Kazuyoshi ^b   Kigawa, Gaku ^b   Nemoto, Hiroshi ^b   Sanada, Yutaka ^b   Hibi, Kenji ^b  

^a GUANGZHOU RED CROSS HOSPITAL   (China)

^b SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ENDONUCLEASE; PROTEIN MUS81; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LIVER RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RISK FACTOR;

ADENOCARCINOMA; AGED; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; DOWN-REGULATION; ENDONUCLEASES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 79952084683     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01790.x     Document Type: Article

References (37)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Sung JJ, Lau JY, Young GP et al. Asia Pacific consensus recommendations for colorectal cancer screening. Gut 2008; 57: 1166-76.
3. Bos JL, Fearon ER, Hamilton SR et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987; 327: 293-7.
4. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990; 249: 912-5.
5. Nishisho I, Nakamura Y, Miyoshi Y et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991; 253: 665-9.
6. Yamazaki T, Hibi K, Takase T et al. PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res 2002; 8: 192-5.
7. Nakayama H, Hibi K, Takase T et al. Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients. Int J Cancer 2003; 105: 491-3.
8. Hibi K, Nakayama H, Kanyama Y et al. Methylation pattern of HLTF gene in digestive tract cancers. Int J Cancer 2003; 104: 433-6.
9. Hibi K, Nakayama H, Kodera Y, Ito K, Akiyama S, Nakao A. CDH13 promoter region is specifically methylated in poorly differentiated colorectal cancer. Br J Cancer 2004; 90: 1030-3.
10. Sakuraba K, Yasuda T, Sakata M et al. Down-regulation of Tip60 gene as a potential marker for the malignancy of colorectal cancer. Anticancer Res 2009; 29: 3953-5.
11. Hibi K, Mizukami H, Shirahata A, Goto T, Sakata M, Sanada Y. Aberrant methylation of the netrin-1 receptor genes UNC5C and DCC detected in advanced colorectal cancer. World J Surg 2009; 33: 1053-7.
12. Tay YD, Wu L. Overlapping roles for Yen1 and Mus81 in cellular Holliday junction processing. J Biol Chem 2010; 285: 11427-32.
13. Chang JH, Kim JJ, Choi JM, Lee JH, Cho Y. Crystal structure of the Mus81-Eme1 complex. Genes Dev 2008; 22: 1093-106.
14. Gaskell LJ, Osman F, Gilbert RJ, Whitby MC. Mus81 cleavage of Holliday junctions: a failsafe for processing meiotic recombination intermediates? EMBO J 2007; 26: 1891-901.
15. Dendouga N, Gao H, Moechars D, Janicot M, Vialard J, McGowan CH. Disruption of murine Mus81 increases genomic instability and DNA damage sensitivity but does not promote tumorigenesis. Mol Cell Biol 2005; 25: 7569-79.
16. McPherson JP, Lemmers B, Chahwan R et al. Involvement of mammalian Mus81 in genome integrity and tumor suppression. Science 2004; 304: 1822-6.
17. Pamidi A, Cardoso R, Hakem A et al. Functional interplay of p53 and Mus81 in DNA damage responses and cancer. Cancer Res 2007; 67: 8527-35.
18. Kai M, Boddy MN, Russell P, Wang TS. Replication checkpoint kinase Cds1 regulates Mus81 to preserve genome integrity during replication stress. Genes Dev 2005; 19: 919-32.
19. Willis N, Rhind N. Mus81, Rhp51(Rad51), and Rqh1 form an epistatic pathway required for the S-phase DNA damage checkpoint. Mol Biol Cell 2009; 20: 819-33.
20. Zeng S, Xiang T, Pandita TK et al. Telomere recombination requires the MUS81 endonuclease. Nat Cell Biol 2009; 11: 616-23.
21. Loizidou MA, Cariolou MA, Neuhausen SL et al. Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population. Breast Cancer Res Treat 2010; 121: 147-56.
22. Jiang Z, Hu J, Li X, Jiang Y, Zhou W, Lu D. Expression analyses of 27 DNA repair genes in astrocytoma by TaqMan low-density array. Neurosci Lett 2006; 409: 112-7.
23. Wu F, Liu SY, Tao YM, Ou DP, Fang F, Yang LY. Decreased expression of methyl methansulfonate and ultraviolet-sensitive gene clone 81 (Mus81) is correlated with a poor prognosis in patients with hepatocellular carcinoma. Cancer 2008; 112: 2002-10.
24. Hiyama T, Katsura M, Yoshihara T et al. Haploinsufficiency of the Mus81-Eme1 endonuclease activates the intra-S-phase and G2/M checkpoints and promotes rereplication in human cells. Nucleic Acids Res 2006; 34: 880-92.
25. Tomoda Y, Katsura M, Okajima M, Hosoya N, Kohno N, Miyagawa K. Functional evidence for Eme1 as a marker of cisplatin resistance. Int J Cancer 2009; 124: 2997-3001.
26. Hibi K, Nakamura H, Hirai A et al. Loss of H19 imprinting in esophageal cancer. Cancer Res 1996; 56: 480-2.
27. Sakakibara T, Hibi K, Koike M et al. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of gastric cancer. Cancer Sci 2006; 97: 395-9.
28. LLeonart ME, Vidal F, Gallardo D et al. New p53 related genes in human tumors: significant downregulation in colon and lung carcinomas. Oncol Rep 2006; 16: 603-8.
29. Pwint TP, Midgley R, Kerr DJ. Regional hepatic chemotherapies in the treatment of colorectal cancer metastases to the liver. Semin Oncol 2010; 37: 149-59.
30. Xu J, Wei Y, Zhong Y et al. Hepatectomy for liver metastasis of colorectal cancer. Int J Colorectal Dis 2009; 24: 419-25.
31. Zeitoun G, Mourra N, Blanché-Koch H et al. Genomic profile of colon cancer metastases. Anticancer Res 2008; 28: 3609-12.
32. Fukunari H, Iwama T, Sugihara K et al. Intratumoral heterogeneity of genetic changes in primary colorectal carcinomas with metastasis. Surg Today 2003; 33: 408-13.
33. Zlobec I, Lugli A. Prognostic and predictive factors in colorectal cancer. J Clin Pathol 2008; 61: 561-9.
34. Ju JH, Chang SC, Wang HS et al. Changes in disease pattern and treatment outcome of colorectal cancer: a review of 5, 474 cases in 20years. Int J Colorectal Dis 2007; 22: 855-62.
35. Sheffer M, Bacolod MD, Zuk O et al. Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci U S A 2009; 106: 7131-6.
36. Sobin LH, Wittekind C. International Union Against Cancer (UICC). TNM classification of malignant tumours. 6th edn New York: Wiley, 2002.
37. Japanese Society for Cancer of the Colon and Rectum. Japanese classification of colorectal carcinoma. 7th edn Tokyo: Kanehara & Co Ltd, 2006.